Peptreon Shares Fall 4.54% to 94,600 Won... Weak Despite Luprone Mexico Approval, Latin America Expansion in Focus
Despite news of Mexican product approval for Luprone (PT105), a long-acting drug developed in-house by Peptreon, the company's share price is showing weakness. On the morning of the 12th in the domestic stock market, Peptreon was trading at 94,600 won, down 4,500 won (4.54%) from the previous day. T

Despite news of Mexican product approval for Luprone (PT105), a long-acting drug developed in-house by Peptreon, the company's share price is showing weakness. On the morning of the 12th in the domestic stock market, Peptreon was trading at 94,600 won, down 4,500 won (4.54%) from the previous day. This is 4,500 won lower than the previous day's closing price of 99,100 won.
With the stock declining even after the approval announcement, the market is watching whether actual supply and sales will fully materialize following the overseas approval.
◆ Luprone Gains Mexico COFEPRIS Product Approval
Peptreon announced on the 9th that its one-month sustained-release leuprolide injection, Luprone (PT105), had received product approval from Mexico's Federal Commission for the Protection against Sanitary Risks (COFEPRIS). The product name approved in Mexico is 'LUPUNIA.'
Luprone is the first commercialized product applying SmartDepot, Peptreon's proprietary long-acting drug delivery platform. SmartDepot is a drug delivery technology designed to release a drug continuously in the body over a set period, and Luprone is a leuprolide injection developed using this technology to maintain efficacy for one month. The active ingredient, leuprolide, is used to treat hormone-dependent diseases such as prostate cancer through hormone regulation.
After securing domestic product approval for Luprone in July last year, Peptreon has now laid the groundwork for pursuing overseas commercialization through this Mexican approval. It is significant in that a self-developed long-acting drug has received approval not only domestically but also from a foreign regulatory authority.
◆ Approval ≠ Sales... Local Follow-up Procedures Are Key
However, product approval and actual revenue generation must be distinguished. To fully launch product sales in Mexico, follow-up procedures necessary for local supply, distribution, and sales must proceed.
Peptreon plans to use Mexico as a strategic hub for entering the Central and South American market. The company said it is proceeding with procedures needed for local supply and sales and pursuing business partnerships. It intends to expand its business into Central and South America, taking into account country-specific approval requirements and market conditions.
The growth of the Central and South American market for leuprolide-based anticancer drugs is also drawing attention. According to figures released by Peptreon, the market grew from 14.68 million dollars in 2018 to 35.79 million dollars in 2023. That is an expansion of about 2.44 times over five years, with an increase of 21.11 million dollars and a growth rate of about 143.8%.
However, these figures reflect the market size up to 2023 and do not indicate the current market size or future growth rate. Nor does the overall Central and South American market size translate directly into Peptreon's actual revenue. Actual business performance may vary depending on local sales prices, supply volumes, distribution network secured, and market competition with rival products.
◆ Stock Decline Not Necessarily a Negative Assessment of the Approval
In terms of share price, short-term market movements are diverging from the Mexican approval news. Peptreon is down 4.54% from the previous day at 94,600 won. However, it is difficult to conclude that the current decline reflects a negative market assessment of the Mexican approval. Trading volume, trading trends by investor type, and the overall biotech sector trend need to be examined further.
Going forward, the market is expected to focus on follow-up procedures for local sales in Mexico, the securing of business partnerships, the timing of actual supply contracts and revenue generation. In particular, it will be important to see whether Luprone, which has now obtained approval in Mexico following Korea, can achieve tangible sales results in the Central and South American market.
Peptreon plans to gradually expand its global supply chain and sales foundation on the occasion of the Mexican approval. If sales results for its self-developed drugs occur in overseas markets, this could serve as evidence for evaluating the commercialization performance of its long-acting drug delivery platform.
Even amid a decline of more than 4%, attention is focused on the progress of Luprone's overseas commercialization and whether it will enter additional countries.
[Some AI assistance was used in writing this article. This article does not recommend buying or selling any specific stock; investment decisions and responsibilities rest with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


